Ovarian Transposition Surgery in India
Get Ovarian Transposition Surgery at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Ovarian Transposition Surgery in UAE
Ovarian Transposition Surgery at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Ovarian Transposition (Oophoropexy) is a fertility-preserving gynaecological procedure that surgically repositions one or both ovaries outside the anticipated radiation field prior to pelvic radiotherapy, protecting ovarian function and hormonal reserve in women of reproductive age facing cancer treatment. The procedure carries an ovarian function preservation rate of approximately 70–90% when performed by experienced minimally invasive gynaecological surgeons, making technique and timing critical to outcomes. GAF Healthcare connects international patients with JCI- and NABH-accredited centres in India and JCI- and DHA-accredited hospitals in the UAE, offering end-to-end case coordination, pre-operative oncology review, and post-operative endocrine monitoring at a fraction of Western costs.
Hospital Stay: 1–2 days (laparoscopic approach); up to 3–4 days if combined with staging or open surgery • Total Stay in Country (Fit-to-Fly): 1–2 weeks for laparoscopic oophoropexy; 3–4 weeks if open or combined oncological procedure • Success Rate: 70–90% ovarian function preservation rate (endocrine); up to 60–65% live-birth rate when combined with assisted reproduction post-treatment
What Is It?
Ovarian Transposition (Oophoropexy) is a surgical fertility-preservation strategy performed in women of reproductive age who are scheduled to receive pelvic or para-aortic radiation therapy for malignancies such as cervical cancer, rectal cancer, Hodgkin lymphoma, or other pelvic tumours. The procedure involves mobilising the ovary on its vascular pedicle — preserving the infundibulopelvic ligament and utero-ovarian ligament blood supply — and anchoring it to the paracolic gutter, the iliac fossa, or above the iliac crest, well outside the anticipated radiation field (typically >3 cm from the field border). Titanium or absorbable surgical clips are placed to mark the transposed ovary, enabling radiologists to exclude it during treatment planning on CT simulation.
From a physiological standpoint, the ovaries are exquisitely radiosensitive; doses as low as 2–6 Gy can permanently impair primordial follicle reserve, leading to premature ovarian insufficiency (POI), loss of endogenous oestrogen and progesterone, menopausal symptoms, cardiovascular risk, and infertility. In young women facing curative radiation, the consequences of untreated POI extend decades beyond cancer treatment. Oophoropexy reduces the radiation dose received by the transposed ovary to less than 5–10% of the prescribed pelvic dose, provided the transposition distance is adequate, directly mitigating the long-term endocrine and reproductive sequelae.
The current standard of care, as endorsed by the American Society for Reproductive Medicine (ASRM), the European Society of Human Reproduction and Embryology (ESHRE), and the European Society of Gynaecological Oncology (ESGO), is laparoscopic oophoropexy performed 1–2 weeks before the commencement of radiotherapy. The procedure may be performed concurrently with other staging or debulking surgeries under the same anaesthetic to avoid delays to oncological treatment. Robotic-assisted platforms (da Vinci Xi) are increasingly used in high-volume centres in both India and the UAE for precise pedicle dissection and haemostasis, particularly in patients with prior pelvic adhesions or body habitus challenges.
Candidates
• Women of reproductive age (typically 18–40 years; considered up to 45 years depending on ovarian reserve) scheduled for curative pelvic or para-aortic external beam radiotherapy or brachytherapy
• Diagnoses most commonly warranting the procedure: carcinoma of the cervix (FIGO Stage IB–IVA), carcinoma of the rectum or sigmoid colon, Hodgkin lymphoma with mediastinal or inguinal involvement, Ewing sarcoma of the pelvis, and selected cases of anal or vaginal carcinoma
• Patients in whom the ovaries are not directly involved by tumour (confirmed by MRI pelvis with contrast and/or PET-CT)
• Adequate ovarian reserve confirmed on baseline transvaginal ultrasound (antral follicle count ≥5–7) and serum Anti-Müllerian Hormone (AMH ≥0.5 ng/mL)
• Good performance status (ECOG 0–2) permitting general or regional anaesthesia and laparoscopic insufflation
• Required pre-operative diagnostics: MRI pelvis (with and without contrast), PET-CT scan (for lymphoma and cervical cancer staging), transvaginal ultrasound with Doppler, serum AMH, FSH, LH, oestradiol, CA-125 (if ovarian pathology suspected), complete blood count, coagulation profile, and anaesthetic fitness assessment (ECG, chest X-ray, pulmonary function if indicated)
• CONTRAINDICATIONS: Direct ovarian metastasis or peritoneal carcinomatosis on imaging; BRCA1/2 germline mutation carriers where prophylactic oophorectomy may be oncologically preferable; hormone-receptor-positive malignancies where residual ovarian function may be contraindicated (e.g., certain endometrial cancers); known severe pelvic adhesive disease precluding safe laparoscopic access; haemodynamic instability or coagulopathy precluding elective surgery; patients in whom radiation field encompasses the entire abdomen (making transposition ineffective)
Procedure
STANDARD LAPAROSCOPIC OOPHOROPEXY (GOLD STANDARD) The procedure is performed under general anaesthesia via a 3- to 4-port laparoscopic approach. The surgeon identifies the ovary and fallopian tube, dissects the infundibulopelvic ligament to mobilise the ovarian pedicle while preserving the utero-ovarian blood supply, and divides the round ligament and utero-ovarian ligament as needed to gain sufficient pedicle length (typically 8–12 cm of mobilisation required). The ovary is tunnelled retroperitoneally or intraperitoneally and sutured with non-absorbable monofilament (e.g., Prolene 2-0) or absorbable sutures (PDS 2-0) to the peritoneum overlying the paracolic gutter or the anterior abdominal wall, lateral to and above the anterior superior iliac spine. Titanium vascular clips (Hem-o-lok or Liga-clip) are applied at the new ovarian position as radiological markers. Bilateral transposition is performed when both ovaries are to be preserved; unilateral transposition (typically the left ovary, which has a longer pedicle) is performed when one ovary is already compromised. Operative time: 45–90 minutes.
ROBOTIC-ASSISTED OOPHOROPEXY (da Vinci Xi / Si PLATFORM) Offered at high-volume centres in India (Apollo, Fortis, Manipal) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital Dubai), robotic assistance provides 10× magnification, EndoWrist articulation, and tremor filtration — critical advantages when dissecting a long vascular pedicle in a narrow pelvis or in patients with prior abdominal surgery or obesity. The robotic approach facilitates a more precise retroperitoneal tunnelling technique, reducing the risk of pedicle torsion. Operative time: 60–120 minutes. Evidence (Morice et al., Huang et al.) supports equivalent or superior ovarian function preservation rates versus conventional laparoscopy in experienced hands.
SIMULTANEOUS SURGICAL OOPHOROPEXY (CONCURRENT WITH STAGING/DEBULKING) In patients undergoing laparoscopic or open surgical staging for cervical or rectal cancer, oophoropexy is performed under the same anaesthetic to avoid delaying radiotherapy commencement. This approach requires close multidisciplinary team (MDT) coordination between the gynaecological oncologist, radiation oncologist, and the theatre team for intraoperative radiation field simulation planning.
OVARIAN TISSUE CRYOPRESERVATION + OOPHOROPEXY (COMBINED FERTILITY PRESERVATION) For patients at high risk of radiation failure (e.g., large radiation fields, high-dose regimens >20 Gy), oophoropexy may be combined with ovarian cortex cryopreservation or oocyte/embryo cryopreservation (where time before chemotherapy permits controlled ovarian stimulation). This combined strategy, offered at specialist reproductive oncology units in India and the UAE, maximises the probability of future fertility through redundant preservation pathways.
POST-PROCEDURE RADIATION PLANNING INTEGRATION Following surgery, CT simulation for radiotherapy planning must explicitly delineate the transposed ovary (identified by the surgical clips) as an organ at risk (OAR). Modern intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) planning systems (Eclipse, Monaco) can then apply dose constraints (typically Dmean <4–5 Gy to the transposed ovary) to reduce scatter and leakage dose. This radiotherapy planning step is as clinically critical as the surgery itself.
Cost of Ovarian Transposition Surgery: India vs. UAE
The cost of Ovarian Transposition (Oophoropexy) varies significantly depending on the destination, hospital tier, surgical approach (laparoscopic versus robotic-assisted), and whether the procedure is performed in isolation or concurrently with staging surgery. India offers world-class gynaecological oncology expertise at 40–60% lower cost than the UAE, while the UAE provides premium hospital infrastructure, luxury accommodation, and convenient air connectivity for patients from the Middle East, Africa, and Europe. Both destinations offer internationally accredited facilities with experienced surgical teams. The estimates below reflect all-inclusive packages (surgeon fees, anaesthesia, hospital stay, standard medications, operating theatre, and basic post-operative follow-up); PET-CT, MRI, fertility preservation add-ons, and radiation planning are billed separately.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $1,500 – $4,000 | ~54% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $3,500 – $8,500 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-OPERATIVE EVALUATION (Days 1–7 post-arrival or virtual pre-consultation)
• Remote case review by GAF Healthcare's gynaecological oncology panel using uploaded imaging (MRI, PET-CT) and pathology reports
• In-country: Repeat or confirmatory MRI pelvis with contrast, transvaginal ultrasound, serum AMH and hormonal profile, PET-CT (if not recently performed)
• Multidisciplinary Team (MDT) conference involving gynaecological oncologist, radiation oncologist, reproductive medicine specialist, and (if applicable) medical oncologist
• Anaesthetic pre-assessment: ECG, chest X-ray, full blood count, coagulation profile, renal and liver function tests, blood grouping and crossmatch
• Patient counselling session: informed consent covering procedure rationale, risks, expected ovarian function preservation rates, and alternative fertility preservation options
• Radiation oncology consultation for pre-operative field planning and clip placement strategy
PHASE 2 — SURGICAL PROCEDURE (Day 8–10)
• Admission the evening before or morning of surgery; nil-by-mouth from midnight
• Laparoscopic (or robotic-assisted) oophoropexy under general anaesthesia; operative duration 45–120 minutes depending on approach and complexity
• Intraoperative steps: pedicle mobilisation, ovarian transposition to paracolic gutter or above iliac crest, suture fixation, clip marking, laparoscopic port closure
• Recovery room: 2–4 hours post-anaesthetic monitoring; vital signs, pain scoring (NRS), and nausea management with ondansetron and low-dose opioid analgesia
• Transition to ward: oral fluids commenced within 4–6 hours; mobilisation on the evening of surgery
PHASE 3 — IMMEDIATE POST-OPERATIVE PERIOD (Days 1–2 post-surgery / Hospital Stay)
• Pain management: paracetamol 1g QDS + ibuprofen 400mg TDS (if no contraindication) as multimodal analgesia; rescue tramadol 50–100mg PRN
• Prophylactic LMWH (enoxaparin 40mg SC OD) commenced 12 hours post-operatively for VTE prophylaxis, continued for 7–14 days
• Wound inspection: 3–4 laparoscopic port sites (5–12mm); dressing check at 24 hours
• Discharge criteria: tolerating oral diet, ambulating independently, NRS pain score ≤3 on oral analgesia, no fever, normal urine output
• Discharge with written instructions: wound care, activity restrictions, warning symptoms (fever >38°C, severe pelvic pain, bloating suggesting pedicle torsion)
PHASE 4 — EARLY RECOVERY & PRE-FLIGHT PERIOD (Days 3–14)
• Outpatient review at Day 7: wound check, suture/clip removal if non-absorbable sutures used, review of any pathology from intraoperative specimens
• Radiation oncology review with CT simulation to confirm clip position and plan radiotherapy fields with the transposed ovary as an OAR
• Activity: light walking encouraged from Day 1; avoid heavy lifting (>5kg) for 2 weeks; return to desk work at Day 7–10
• Patients undergoing laparoscopic oophoropexy are typically declared fit to fly at Day 10–14, provided no complications
PHASE 5 — RADIOTHERAPY COMMENCEMENT & LONG-TERM FOLLOW-UP
• External beam radiotherapy (EBRT) or chemoradiation typically commences within 2–4 weeks of surgery once wounds have healed
• Ovarian function monitoring post-radiation: serum FSH, LH, oestradiol, and AMH at 3, 6, and 12 months post-treatment
• If POI occurs despite transposition (failure rate ~10–30% depending on scatter dose and field size): hormone replacement therapy (HRT) with oestrogen-progesterone combinations initiated under gynaecological endocrinology supervision
• Fertility assessment (TVS, AMH, AFC) at 12 months post-radiation if patient wishes to pursue conception via natural means, IVF, or ovarian tissue reimplantation
Risks & Considerations
Ovarian Transposition is generally a safe, minimally invasive procedure, but patients and clinicians must be aware of the following specific and general risks. Ovarian failure despite transposition occurs in 10–30% of cases, most commonly due to scatter radiation dose exceeding the ovarian tolerance threshold, particularly when the radiation field is large (e.g., extended-field or whole-pelvis IMRT), when brachytherapy is added, or when the transposed position is suboptimally distant from the field edge. Ovarian pedicle torsion is a rare but serious early complication (reported incidence 1–3%), presenting as acute-onset pelvic or abdominal pain and requiring urgent laparoscopic detorsion; the risk is mitigated by adequate retroperitoneal fixation and avoiding excessive pedicle tension. Ovarian cyst formation (paratubal or functional cysts) at the transposed site occurs in up to 10–15% of patients, the majority of which are benign and resolve spontaneously, though symptomatic cysts may require aspiration or excision. Clip migration is rare with modern Hem-o-lok or titanium clips but can cause confusion on post-operative imaging if not clearly documented in the operative report. General surgical risks include port-site bleeding or hernia (incidence <1% with correct fascial closure), bowel or bladder injury during dissection in patients with pelvic adhesions (rare, <0.5%), wound infection, and anaesthetic complications stratified by ASA class. Return of ovarian function does not guarantee fertility; patients should be counselled that successful hormone preservation does not equal successful conception, and that radiation-related uterine damage (reduced uterine volume, impaired endometrial receptivity) may independently compromise implantation even if the ovary is functional. In BRCA mutation carriers, residual ovarian tissue post-transposition carries an ongoing risk of ovarian malignancy, and the risk-benefit discussion must involve a clinical geneticist and gynaecological oncologist. Patients should also be informed that ovarian tissue at the transposed site carries a theoretical — though extremely low — risk of harbouring micrometastatic disease in high-risk haematological malignancies, which is a formal contraindication in some centres.
Top Hospitals for Ovarian Transposition Surgery
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Aster Hospital Dubai
Dubai, UAE
Top Doctors for Ovarian Transposition Surgery
Internationally trained specialists in Gynecology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Tarang Preet Kaur
MBBS, MS, MRCOG, MCh, Fellowship in Urogynaecology, Fellowship in Cosmetic Gynaecology
Urogynaecologist
Max Super Speciality Hospital, Saket, New Delhi, India
11+ Yearsof experience
Dr. Tarang Preet Kaur is a Consultant in Urogynaecology with over 11 years of clinical experience, currently practicing at Max Super Speciality Hospital, Saket in New Delhi. She holds an MCh in Urogynaecology from Edge Hill University, United Kingdom (2024), the MRCOG from the Royal College of Obstetricians & Gynaecologists, and an MS in Obstetrics & Gynaecology from Maulana Azad Medical College, Delhi. Her dual qualification across India and the UK… Read more
Dr. Amrinder Kaur Bajaj
MBBS, MD — Obstetrics & Gynaecology (Gold Medalist), Senior Residency — Obstetrics & Gynaecology, FRSH — Fellow of the Royal Society of Health, FIAMS — Fellow of the Indian Association of Medical Specialists
Obstetrician & Gynaecologist
Fortis Hospital, Gurgaon, Gurgaon, India
42+ Yearsof experience
Dr. Amrinder Kaur Bajaj is one of Delhi-NCR's most experienced gynaecologists, with over four decades spent caring for women at every stage of life. She currently practises as a Consultant in Obstetrics & Gynaecology at Fortis Hospital, Gurgaon, where she brings together deep clinical knowledge and a quietly reassuring bedside manner that patients — and their families — find genuinely comforting. Her academic journey set a high bar early on. She completed… Read more
Dr. Anuradha Khurana
MBBS, DGO (Diploma in Obstetrics & Gynaecology), PG in High Risk Pregnancy and Infertility
Gynecologist & Obstetrics Specialist
Artemis Hospital, New Delhi, India
20+ Yearsof experience
Dr. Anuradha Khurana is a Senior Consultant in Obstetrics and Gynecology at Artemis Hospital, Delhi, with over two decades of hands-on experience in women's health. She is particularly well regarded for her work in high-risk pregnancy management, uterine conditions like fibroids and endometriosis, and complex gynecological surgeries. Patients and families consistently describe her as someone who takes the time to truly listen — and to explain things in a… Read more
Dr. Aswari Kesari Kapoor
MBBS, DGO (Diploma in Gynaecology & Obstetrics), CPS (College of Physicians and Surgeons), DNB (Diplomate of National Board) — Obstetrics & Gynaecology
Obstetrician & Gynecologist
Indraprastha Apollo Hospital, New Delhi, India
23+ Yearsof experience
Dr. Aswari Kesari Kapoor is a seasoned Obstetrician and Gynecologist with over 23 years of hands-on clinical experience. She practices at Indraprastha Apollo Hospital in New Delhi — one of India's most respected multi-specialty institutions. Over the course of her career, she has built a strong reputation for managing complex gynecological conditions alongside high-risk pregnancies, all with a calm and reassuring bedside manner that patients consistently… Read more
Dr. Bindhu K S
MBBS, DNB (Obstetrics & Gynecology), Fellowship in Minimal Access Surgery, FICOG (Fellowship of the Indian College of Obstetricians and Gynaecologists), Certificate in Gynecologic and Obstetric Sonography, Certificate in Appreciation of Well Being in Fetal Heart Disease
Obstetrician & Gynecologist
Apollo Hospitals, Navi Mumbai, Mumbai, India
23+ Yearsof experience
Dr. Bindhu K S is a seasoned Obstetrician and Gynecologist based in Mumbai, currently practicing at Apollo Hospitals, Navi Mumbai. With over two decades of clinical experience, she brings together expertise in both obstetrics and advanced minimally invasive gynecologic surgery. Whether a patient comes with a complex fibroid, troublesome endometriosis, or a high-risk pregnancy, Dr. Bindhu approaches each situation with careful thought and genuine care. Her… Read more
Frequently Asked Questions — Ovarian Transposition Surgery
The estimated all-inclusive cost of Ovarian Transposition (Oophoropexy) in India ranges from approximately USD 1,500 to USD 4,000, depending on the hospital tier (NABH- or JCI-accredited centres such as Apollo Hospitals, Fortis Healthcare, or Manipal Hospitals), the surgical approach (standard laparoscopic versus robotic-assisted via the da Vinci Xi platform), and whether the procedure is performed in isolation or concurrently with oncological staging surgery. In the UAE (Dubai or Abu Dhabi), the equivalent procedure at JCI- and DHA-accredited institutions such as Cleveland Clinic Abu Dhabi, Mediclinic City Hospital, or American Hospital Dubai ranges from approximately USD 3,500 to USD 8,500, reflecting the premium hospital infrastructure, luxury patient services, and higher operating costs. India is typically 40–60% less expensive than the UAE for this procedure, while maintaining equivalent surgical expertise and international accreditation standards. These estimates generally include surgeon and anaesthetist fees, operating theatre costs, 1–2 nights of hospital stay, standard post-operative medications, and one follow-up consultation. Additional costs — including pre-operative MRI pelvis, PET-CT scan, serum AMH and hormonal profiling, fertility preservation procedures (oocyte or ovarian tissue cryopreservation), and subsequent radiotherapy planning — are billed separately and should be clarified with your GAF Healthcare case coordinator before finalising your treatment plan.
For patients undergoing laparoscopic or robotic-assisted Ovarian Transposition as a standalone procedure, the typical fit-to-fly window is 10–14 days from the date of surgery. The hospital stay itself is short — usually 1 to 2 nights — but patients must remain in-country for a post-operative review at Day 7, during which wound healing is assessed, sutures or clips are checked, and a confirmatory CT simulation with the radiation oncology team is often performed to verify the transposed ovary's position relative to the planned radiation field before the patient travels. Flying too early carries a risk of deep vein thrombosis (DVT) due to prolonged immobility combined with the post-surgical prothrombotic state; LMWH thromboprophylaxis (enoxaparin 40mg daily, subcutaneous) is typically prescribed for 7–14 days post-operatively and must be continued during and after the flight. If Oophoropexy is performed concurrently with open staging surgery or bowel resection as part of a combined oncological procedure, the fit-to-fly period extends to 3–4 weeks, reflecting the longer recovery required for larger incisions and more extensive dissection. Your GAF Healthcare case coordinator will obtain a formal fit-to-fly clearance letter from your treating surgeon before your departure date is confirmed, and will arrange airport wheelchair assistance and an aisle seat for comfort during the flight home.
The success rate of Ovarian Transposition (Oophoropexy) depends on how 'success' is defined — endocrine (hormonal) function preservation versus fertility (live birth) outcomes — and on several procedure- and patient-specific variables. In terms of ovarian endocrine function preservation (avoidance of premature ovarian insufficiency or POI), published evidence reports success rates of approximately 70–90% when the procedure is performed by an experienced gynaecological oncologist using correct laparoscopic or robotic technique, the transposed ovary is positioned at least 3 cm outside the radiation field border, and the radiotherapy team actively excludes the marked ovary as an organ at risk (OAR) during IMRT or VMAT planning. The primary cause of endocrine failure despite technically successful transposition is scatter and leakage radiation dose, which is higher with brachytherapy, extended-field EBRT, or large pelvic fields. In terms of subsequent fertility outcomes, the live-birth rate following Oophoropexy and pelvic radiotherapy is lower — estimated at 50–65% among women who retain ovarian function and subsequently attempt conception via natural intercourse or IVF — due to co-existing radiation-related uterine damage (reduced uterine compliance and endometrial receptivity) even when the ovary itself remains functional. At GAF Healthcare partner centres in India and the UAE, high-volume surgical experience (>50 oophoropexies per year at flagship centres), integration of robotic platforms for precision pedicle dissection, and close MDT coordination with radiation oncology and reproductive medicine teams contribute to outcomes that are consistent with or exceed published international benchmarks.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end medical travel coordination for patients travelling to India or the UAE for Ovarian Transposition, managing every logistical detail so patients and their families can focus entirely on treatment and recovery.
INDIA — VISA & ENTRY: GAF Healthcare facilitates the e-Medical Visa (e-MV) application for India, which allows a stay of up to 60 days (triple-entry) and is available to citizens of 156+ countries. The e-MV is typically approved within 72 hours. An accompanying e-Medical Attendant Visa (e-MAV) is simultaneously arranged for one family member or caregiver. GAF's India desk provides a formal Medical Visa Support Letter (MVSL) from the treating hospital, which is a mandatory document for the application.
UAE — VISA & ENTRY: Citizens of 100+ countries qualify for visa-free entry or visa-on-arrival to the UAE for 30–90 days, covering the typical treatment and recovery period. For patients from countries requiring a pre-arranged visa, GAF Healthcare coordinates a UAE Medical Tourist Visa through the Dubai Health Authority (DHA) or Department of Health Abu Dhabi (DoH) frameworks, including the required medical appointment confirmation letters.
AIRPORT & GROUND TRANSFERS: Private ambulance-assisted or wheelchair-enabled airport-to-hospital transfers are arranged for arrival and departure, with a GAF coordinator present to receive patients. All inter-facility transfers (e.g., hospital to imaging centre, hospital to hotel) are managed by a dedicated ground logistics team.
DEDICATED PATIENT COORDINATORS & INTERPRETERS: Each patient is assigned a named GAF Healthcare case manager who speaks the patient's primary language (Arabic, Russian, French, Swahili, and others available). Medical interpreters fluent in clinical terminology accompany patients during surgical consultations, MDT meetings, informed consent discussions, and radiotherapy planning sessions.
ACCOMMODATION: GAF Healthcare arranges verified accommodation for patients and their attendants within 1–3 km of the treating hospital, ranging from serviced apartments to partner hotels, depending on budget and medical requirements. Accessible rooms, meal-delivery services, and 24-hour on-call support are standard inclusions for all GAF-coordinated stays.
TELEMEDICINE FOLLOW-UP: Post-discharge and after the patient has returned home, GAF Healthcare facilitates remote follow-up consultations between the treating gynaecological oncologist or radiation oncologist and the patient's home-country physician, including secure transmission of operative reports, clip-position imaging, and post-radiation hormonal monitoring results.